Tharimmune, Inc. Enters Material Definitive Agreement

Ticker: CNTN · Form: 8-K · Filed: Jul 31, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateJul 31, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, company-name-change

TL;DR

Tharimmune just signed a big deal, filing an 8-K on 7/25/25.

AI Summary

On July 25, 2025, Tharimmune, Inc. entered into a material definitive agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in Delaware and has its principal executive offices in Red Bank, NJ.

Why It Matters

This filing indicates a significant new agreement for Tharimmune, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

FAQ

What type of material definitive agreement did Tharimmune, Inc. enter into?

The filing states that Tharimmune, Inc. entered into a material definitive agreement on July 25, 2025, but does not specify the nature of the agreement.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on July 25, 2025.

What was Tharimmune, Inc. previously known as?

Tharimmune, Inc. was previously known as Hillstream BioPharma Inc.

In which state is Tharimmune, Inc. incorporated?

Tharimmune, Inc. is incorporated in Delaware.

What is the address of Tharimmune, Inc.'s principal executive offices?

The address of Tharimmune, Inc.'s principal executive offices is 34 Shrewsbury Avenue, Suite 1C, Red Bank, NJ 07701.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 31, 2025 regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing